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50 The Journal of Thoracic and Cardiobjective: We analyzed the survival, clinical course, and role of prosthesis–patient
ismatch after systemic atrioventricular valve replacement in children.
ethods: From 1974 to 2006, 69 patients underwent systemic atrioventricular valve
eplacement (median age 1.2 years, range 1.1 months to 5.4 years), with 17 patients
equiring re-replacement of the systemic atrioventricular valve. Prosthesis–patient
elationship was analyzed by comparing (1) the prosthetic valve diameter and the
redicted annulus diameter based on the body surface area and (2) the prosthetic
alve diameter and the measured annulus diameter.
esults: Survival was 73% at 1 year and 65% at 5, 10, and 15 years. Age, weight,
ody surface area, predicted annulus diameter, prior surgery, underlying disease,
nd ratio of prosthetic valve diameter to body weight were significant predictors of
eath. Variables associated with re-replacement of the systemic atrioventricular
alve were body surface area, prosthetic valve diameter, predicted annulus diameter,
nd presence of multiple left-sided obstructive lesions. The majority of patients
eceived a prosthesis larger than the predicted annulus diameter. There was good
orrelation between the prosthetic valve diameter and the measured annulus diam-
ter (r  0.85). Mismatch, as described by the difference in z scores of prosthetic
alve diameter and measured annulus diameter, was not a significant predictor of
eath or re-replacement of the systemic atrioventricular valve.
onclusions: Although valve replacement is considered the last therapeutic option
fter failed attempts of valvuloplasty, long-term outcome is favorable. Selection of
he prosthesis is made on the basis of the measured annulus diameter. An elevated
atio of prosthetic valve diameter to body weight is associated with patients with low
ody weight or a large native annulus in dilated ventricles.
alve repair is the treatment of choice in dysfunction of the systemic
atrioventricular valve, and refined techniques for both stenotic and regur-
gitant valves are available.1 Nonetheless, a subset of patients may still
equire systemic atrioventricular valve replacement (AVVR) after failed attempts of
alvuloplasty.2 The small size of the native valve annulus, atrium, and ventricle pose
roblems that are unique in children. Early mortality after AVVR during the first
ears of life remains high, and the risks of lifelong anticoagulation, subsequent
alve replacement, and deterioration of ventricular function have to be taken into
ccount when considering this therapeutic option.3-6 AVVR can be performed with
bioprosthesis or mechanical prosthesis. Despite the need for lifelong anticoagu-
ation, mechanical valves remain the preferred valves because of their low profile,
xcellent hemodynamic properties, and durability, and the tendency of bioprosthe-
es to early calcification.7,8 Patients who require AVVR during early infancy often
ndergo multiple surgical interventions for a multitude of concomitant lesions,
vascular Surgery ● September 2007
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Daking comparison of anatomic and clinical features diffi-
ult. Despite the heterogeneity of study groups, risk factors
or early death and subsequent valve replacement have been
stablished in previous publications.3,9,10
Age and weight at first AVVR and the presence of
trioventricular septal defect (AVSD) or left-sided obstruc-
ive lesions have been identified to be related to poor clin-
cal outcome. In addition to the importance of these param-
ters, several publications have focused on the role of
rosthesis–patient mismatch as an important predictor for
atient outcome.3,11 In this study we report on our experi-
nce with AVVR with special emphasis on the role of
rosthesis–patient mismatch.
aterials and Methods
atients
atients who underwent AVVR with a mechanical prosthesis
etween 1974 and 2006 at our institution were identified from a
omputerized database. Patient charts, catheterization records, and
perative data were studied retrospectively. Collected data in-
luded age, weight, and body surface area (BSA) at AVVR,
iagnosis, number of operations and surgical valvuloplasties be-
ore AVVR, and type and size of prosthesis. Five patients under-
ent AVVR with a bioprosthesis before mechanical AVVR. Those
atients were included in the study group when the bioprosthesis
as replaced by a mechanical valve within the first 6 years of life.
atients were followed until the time of last clinical visit or death.
ollow-up was complete in all patients. The study was approved
y the institutional research ethics board.
tatistical Analysis
nalysis of data was performed with the Statistical Package for the
ocial Sciences Version 14.0 (SPSS Inc, Chicago, Ill). Data are
eported as frequencies and median with ranges. Curves for sur-
ival and freedom from repeated AVVR were obtained by the
aplan–Meier method. Predictors of time to the event of death or
ubsequent AVVR (re-AVVR) were studied by a log-rank test for
ategoric variables and a Cox regression model with univariate and
ge-adjusted multivariate analysis for continuous variables.
easurement of Atrioventricular Valve Size
he predicted annulus diameter (PAD) was calculated on the basis
f the patients’ BSA.12 Measured annulus diameter (MAD) was
ssessed by echocardiography in the 4-chamber view from hinge
oint to hinge point in 43 patients before surgical intervention. In
Abbreviations and Acronyms
AVSD  atrioventricular septal defect
AVVR atrioventricular valve replacement
BSA  body surface area
MAD measured annulus diameter
PAD  predicted annulus diameter
PVD  prosthetic valve diameterpatients in whom echocardiography was not available, assess- b
The Journal of Thoracicent of MAD was done on angiography. The z score of the
atients’ MAD was calculated as described by Daubeney and
olleagues.12 In the same way, we calculated the z score of the
rosthetic valve diameter (PVD). The degree of prosthesis–patient
ismatch was defined as the difference between the z score of
VD and the z score of the MAD as previously described.11 The
resence of stenosis or regurgitation was estimated by color Dopp-
er and pulsed-wave Doppler.
esults
atient Characteristics
total of 88 mechanical AVVRs were performed in 69 pa-
ients (34 male, 35 female), with 17 patients requiring re-
VVR and 2 patients requiring a third AVVR (re-re-AVVR).
ongenital heart disease was the underlying cause for valve
eplacement in all patients. Of the 61 patients with biventricu-
ar circulation, 59 patients had a left systemic ventricle and
eplacement of the mitral valve and 2 patients had a right
ystemic ventricle and replacement of the tricuspid valve. In 8
atients with functionally univentricular hearts, 6 patients had
eplacement of the tricuspid valve and 2 patients had replace-
ent of the mitral valve. Patient characteristics and age distri-
ABLE 1. Patient characteristics at initial atrioventricular
alve replacement
ge at first AVVR 1.2 y (0.09–5.4)
eight at first AVVR 7.1 kg (3.2–16.7)
SA 0.38 m2 (0.20–0.72)
VD 19 mm (15–29)
rosthesis/weight ratio 2.5 mm/kg (1.2–5.1)
AD 16.7 mm (12.4–20.5)
AD* 19 mm (11–40)
score MAD* 1.2 (3.8–8.11)
ollow-up 3.4 y (0.6–28.4)
egurgitation n 37 (54%)
tenosis n 20 (29%)
ombined lesion n 12 (17%)
ardiac defect
AVSD n 22 (32%)
Left-sided obstructions n 16 (23%)
“Isolated” valve anomaly n 17 (25%)
Univentricular heart n 8 (11%)
Other cardiac defects n 6 (9%)
rosthesis type
Carbomedics (Austin, Tex) n 33 (48%)
St Jude Medical (St Paul, Minn) n 26 (38%)
Björk Shiley (Irvine, Calif) n 5 (7%)
American Thoracic Society
(New York, NY)
n  4 (6%)
Omnicarbon (Inver Grove
Heights, Minn)
n  1 (1%)
VVR, Atrioventricular valve replacement; BSA, body surface area; PVD,
rosthetic valve diameter; PAD, predicted annulus diameter; AVSD, atrio-
entricular septal defect; MAD, measured annulus diameter. *Measure-
ent was available in 51 of 69 patients (74%).ution are summarized in Table 1 and Figure 1.
and Cardiovascular Surgery ● Volume 134, Number 3 751
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DA total of 85 operations were performed in 53 patients
77%) before first AVVR, including 37 valvuloplasties of
he systemic atrioventricular valve in 32 patients (46%,
ncluding repair of AVSD) and 5 valve replacements with a
ioprosthesis in 5 patients (7%). In 17 patients (25%) con-
omitant surgery was performed at the time of AVVR. In 2
atients the prosthesis was placed in a supra-annular posi-
ion because of the small dimension of the native annulus.
ll patients were placed on oral anticoagulation therapy
ith phenprocoumon or warfarin sodium, aiming at an
nternational normalized ratio between 2.5 and 3.5.
igure 1. Age distribution of patients (n  69) at time of first
VVR. AVVR, Atrioventricular valve replacement.
ABLE 2. Comparison between survivors and nonsurvivors
Survivors
n  47
ge at first AVVR 1.4 y (1.1 mo–5.4 y)
eight at first AVVR 8.1 kg (4.1–16.7)
ody surface 0.40 m2 (0.23–0.72)
rior surgery 33
rior valvuloplasty 20
oncomitant surgery 13
VD 17 mm (16–29)
rosthesis/weight ratio 2.3 mm/kg (1.2–4.5)
AD 17.1 mm (13.2–22.5)
AD* 19.2 mm (12–40)
score difference*
1 (“oversized”) 7/38 (18%)
1 1 (“matched”) 17/38 (45%)
1 (“undersized”) 14/38 (37%)
ardiac defect
AVSD 12
Left-sided obstructions 12
Isolated valve anomaly 15
Univentricular heart 3
Other cardiac defects 5
VVR, Atrioventricular valve replacement; PVD, prosthetic valve diameter
trioventricular septal defect. *Measurement was available in 51 of 69 patients
52 The Journal of Thoracic and Cardiovascular Surgery ● Septeurvival and Predictors of Death
urvival for the entire cohort was 73% at 1 year and 65% at
, 10, and 15 years. Among the total of 22 deaths, 20
atients died after first AVVR and 2 patients died after
e-AVVR; 8 of 20 deaths after first AVVR occurred within
0 days after operation (early mortality 11%). The 2 patients
ho died after re-AVVR had urgent re-AVVR for acute
alve thrombosis (1 intraoperative death, 1 death 3 months
fter re-AVVR).
Univariate analysis of survival revealed age, weight,
SA, PAD, ratio of PVD to body weight at first AVVR,
rior surgery, presence of AVSD, and functionally univen-
ricular heart to be predictors of death. The presence of
solated valve disease was associated with a significantly
etter survival (Table 2, Figure 2). Whereas an elevated
atio of PVD to body weight was associated with poor
utcome, the z score difference as a measure for prosthesis–
atient mismatch did not reach statistical significance. Age-
djusted multivariate analysis showed significant difference
or the ratio of PVD to body weight and the presence of
VSD. Survival in the presence of isolated valve anomaly
as significantly better.
omplications
omplications in the survivors included complete atrioven-
ricular block requiring pacemaker implantation in 7 pa-
ients (11%, 6 patients after first AVVR, 1 patient after
e-AVVR). Major hemolysis did not develop in any patient.
Nonsurvivors
n  22
P
univariate
P
multivariate
0.7 y (2.3 mo–3.7 y) .048
5.6 kg (3.2–14.2) .024 .32
0.30 m2 (0.2–0.65) .018 .21
20 .04 .06
12 .35 .27
4 .24 .08
19 mm (15–23) .426 .43
3.5 mm/kg (1.6–5.2) .001 .02
15.1 mm (12.4–21.5) .014 .17
15.5 mm (11–35) .234 .52
4/13 (31%) .35 .38
5/13 (38%) .75 .73
4/13 (31%) .09 .08
10 .039 .05
4 .36 .45
2 .035 .05
5 .037 .16
1 .55 .73
, predicted annulus diameter; MAD, measured annulus diameter; AVSD,; PAD
(74%).
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Dlthough small paravalvular leaks occurred occasionally,
o patient required reoperation for this reason. Fatal intra-
ranial hemorrhage occurred in 1 infant at the age of 18
onths in the presence of an international normalized ratio
reater than the normal range. Seven patients had acute
alve dysfunction because of prosthetic valve thrombosis or
eaflet entrapment by pannus formation requiring re-AVVR.
emiparesis developed in 1 patient shortly after AVVR, but
ymptoms resolved entirely. One patient had intermittent
trial fibrillation at the age of 15 years, 11 years after the
rst AVVR. Replacement of the prosthetic valve was per-
ormed because the transprosthetic gradient and systolic
ulmonary artery pressure were elevated, but atrial fibrilla-
ion recurred. This patient had successful ablation of his
rrhythmia and is currently in sinus rhythm. No case of
rosthetic valve endocarditis occurred.
ndication, Timing, and Risk Factors for Subsequent
eplacement of the Systemic Atrioventricular Valve
f 88 AVVRs, 19 were subsequent AVVRs with 17 re-
VVRs and 2 re-re-AVVRs (median age at initial AVVR
.2 years, range 1.1 months to 5.4 years). Freedom from
e-AVVR for the entire cohort was 91% at 1 year, 86% at 5
ears, 49% at 10 years, and 37% at 15 years from first
VVR (Figure 3). Mechanical valves were used for all
e-AVVRs. Freedom from re-AVVR was characterized by a
mall but steady number of early replacements during the
rst years and a steep decrease at 7 to 10 years after the
nitial AVVR. Indications for subsequent AVVR were acute
ysfunction caused by valve thrombosis or leaflet entrap-
igure 2. Survival for diagnosis-related groups (n  69). AVSD,
trioventricular septal defect; AVVR, atrioventricular valve
eplacement.ent by pannus formation in 7 patients and progressive (
The Journal of Thoracictenosis caused by patient growth in 12 patients. Three
atients with acute valve thrombosis received thrombolytic
herapy, but all still required re-AVVR. Re-AVVR was
erformed at an interval of 5.7 years (range 1 month to 10.7
ears) from the first AVVR at an age of 6.5 years (range 2
onths to 16.1 years). At this point, body weight had
ncreased from 6.7 kg (range 4.1–16.7 kg) to 16.9 kg (range
.1–57.3 kg). The diastolic mean gradient across the me-
hanical valve on echocardiography was 14 mm Hg (range
0–18), and all but 1 patient had elevated systolic pulmo-
ary artery pressure as assessed by catheterization before
e-AVVR (median 53 mm Hg, range 25–84 mm Hg).
The PVD of the initially implanted valve was 17 mm
range 15–29 mm), and the PVD of the newly implanted
alve was 21 mm (range 16–31 mm). In all patients who
nderwent re-AVVR for progressive stenosis caused by
atient growth, a prosthesis larger than the initial prosthesis
ould be implanted. Average valve size increase in all 17
atients was 3 mm (range 0–8 mm).
For the analysis of predictors of re-AVVR, we included
ll survivors of first AVVR (n  49) to compare patients
equiring re-AVVR (n 17) with patients who did not (n
2). BSA, PVD, PAD, and the presence of multiple left-
ided obstructive lesions were associated with a higher risk
or re-AVVR.
rosthesis–Patient Relationship
ssessment of the MAD before AVVR was available in 51
f 69 patients (74%). The median PAD for these patients
as 16.7 mm (range 12.4–22.5 mm). The median MAD
as 19 mm (range 11–40 mm) with a median z score of 1.2
igure 3. Freedom from re-AVVR. AVVR, Atrioventricular valve
eplacement.range 3.8 to 8.11), and the median PVD was 19 mm
and Cardiovascular Surgery ● Volume 134, Number 3 753
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Drange 15–29) with a median z score of 1.44 (range 2.17
o 4.61).
Figure 4, A and B, shows the relationship between PVD
nd PAD and the relationship between PVD and MAD. As
hown in Figure 4, A, the majority of patients received a
rosthesis that was larger than the PAD, and there was only
oor correlation between these 2 parameters (r  0.62).
hen comparing the PVD and the MAD (Figure 4, B), we
ound good correlation between these 2 parameters (r 
.85).
Prosthesis–patient mismatch was defined as the differ-
nce between z scores of PVD and MAD. The median z
core difference (z score PVD  z score MAD) was 0.51
range 5.13 to 3.14). As proposed by Eble and col-
eagues,11 “oversizing” of the prosthetic valve was noted to
e present when the z score difference was greater than 1.
Undersizing” was present when the difference was less
han 1 (Figure 5). Because the smallest available prosthe-
is had a diameter of 16 mm (only one 15-mm prosthesis
as used), “oversizing” was present in 11 patients (21%)
igure 5. Z score difference (z score PVD  z score MAD) as a
easure of geometric disparity in relation to MAD. Survivors
closed circles) and nonsurvivors (open circles). MAD, Measuredlnnulus diameter.
54 The Journal of Thoracic and Cardiovascular Surgery ● Septeith a MAD less than 19 mm. “Undersizing” was present in
8 patients (35%), and data were skewed to patients with a
arge MAD. Mismatch, defined on this basis, did not reach
ignificant difference between survivors and nonsurvivors
Table 2) and between patients requiring re-AVVR and
atients who did not.
iscussion
o our knowledge, the present report is the largest single-
enter study on AVVR during the first years of life, whereas
ost single-center studies refer to a limited number of
atients despite inclusion of patients up to 18 years old.4,6,9
urvival Analysis
arly mortality was 11% in this study, which is comparable
o other reports in which early mortality after initial AVVR
anges from 11% to 20%.4,6,10 Early mortality after valve
eplacement during the first 2 years of life is reported to be
ven higher. In our series, 30-day mortality in children aged
ess than 2 years was 13%. Other authors reported an early
ortality of 36% and 52% in this subgroup,4,13 but there are
lso reports of small series with an early mortality of 14%
o 20%.9,10,14 After hospital discharge, there are few deaths
nd long-term survival is favorable with only a moderate
mpairment in general health status for school-aged children
nd a near-normal quality of life for the majority of adoles-
ents and young adults.15 Long-term survival in our series
as somewhat lower than that reported by other authors,3,4,9
hich is likely because we included children aged less than
years and a relatively high proportion of patients with
unctionally univentricular hearts, who are known to be
igh-risk patients.
Despite the dramatic progress in intraoperative manage-
ent and postoperative care, and a study time of 32 years,
e were not able to assess statistically significant improve-
ent in survival over time. This may be attributable to the
eterogeneity of the study group with a broad spectrum of
nderlying cardiac diseases. Nonetheless, Alexiou and col-
Figure 4. A, Relationship between PVD and PAD.
The majority of patients received a prosthesis
with a PVD larger than the PAD (points above the
line). B, Relationship between PVD and MAD.
PVDMAD (line). Survivors (closed circles) and
nonsurvivors (open circles). PVD, Prosthetic
valve diameter; PAD, predicted annulus diame-
ter; MAD, measured annulus diameter.eagues9 showed a decrease in operative mortality from
mber 2007
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D1% before 1990 to 3.6% after 1990. In addition to the role
f age, weight, BSA, PAD, ratio of PVD to body weight,
nd diagnosis for survival, as shown in other studies,3,12,16
e found prior surgery to be related with higher mortality.
ubsequent Valve Replacement
e-AVVR is almost inevitable in children. Ten-year free-
om from re-AVVR was 49% in this study, meaning that
pproximately half of the survivors require subsequent
VVR within 10 years. This is comparable to other studies
n which 10-year freedom from re-AVVR was 56%.6,17
iologic valves show rapid deterioration with time and
ometimes need to be replaced within months.8 Therefore,
e only use biologic valves occasionally when proper man-
gement of anticoagulation is not ensured. The two main
ndications for re-AVVR after mechanical AVVR were
rogressive stenosis caused by patient growth and acute
ysfunction caused by thrombosis or leaflet entrapment by
annus formation, whereas prosthetic valve endocarditis,
aravalvular leak, regurgitation, and left ventricular outflow
ract obstruction were not encountered in our series. A
ulti-institutional study from the Pediatric Cardiac Care
onsortium18 showed that the need for re-AVVR highly
epends on the prosthesis size and the patient’s age at initial
VVR. When 10-year freedom from re-AVVR is com-
ared, the fact of inclusion of patients up to 18 years old4,19
as to be taken into account.
A matter of concern is the timing of re-AVVR. Whereas
he indication for re-AVVR is not debatable in acute dys-
unction after a failed attempt of thrombolysis in valve
hrombosis, re-AVVR for progressive stenosis is less
learly defined. Cardiac catheterization was proposed once
he maximum transprosthesis flow velocity exceeds 270
m/s.17 At our institution we opt for cardiac catheterization
s soon as there are signs of elevated right ventricular
ressure on echocardiography, in addition to a mean
ransprosthetic gradient greater than 12 mm Hg. An increase
n BSA20 or body weight21 of approximately 2 or 2.5 times
f that at initial implantation is not suitable for timing,
ecause no significant difference in rate of weight gain
mong patients who required subsequent AVVR and pa-
ients who did not was observed.18
In all of our patients with re-AVVR for progressive
tenosis, the new valve could be upsized. Although “fixing”
f the native valve annulus to the sewing ring of the pros-
hetic valve was considered to hinder further growth of the
ative annulus, all studies reporting on subsequent AVVR
howed a sufficient gain in prosthesis size at re-
VVR,10,18,19,22 suggesting that there is persisting annular
rowth.
Mortality after subsequent AVVR is low.18 In our series
here were only 2 deaths after re-AVVR. Re-AVVR was
erformed in the presence of an acutely thrombosed valve in p
The Journal of Thoracicoth patients, and both patients were in poor clinical
ondition.
rosthesis–Patient Mismatch
rior studies have focused on the role of an increased ratio
f PVD to body weight as a predictor of adverse outcome.3
he majority of our patients received a prosthesis that was
arger than the predicted annulus size, resulting in an ele-
ated ratio of PVD to body weight. These patients represent,
t least in part, 2 subsets of patients: (1) small children with
ow body weight in whom selection of a “too-large” pros-
hesis was inevitable because of the lack of smaller pros-
hesis and (2) patients in whom a smaller prosthesis would
ave been available but was not implanted because of large
nnulus dimensions in highly dilated ventricles or patients
ith univentricular hearts. Selection of a prosthesis larger
han the PAD was not made for the incentive to avoid
atient outgrowth but to implant a prosthesis that fitted the
ctual size of the annulus as shown by the relationship
etween PVD and MAD. In dilated ventricles with a large
AD, the PVD tended to be even smaller than the MAD,
nd in these patients a prosthetic valve was chosen as close
o the PAD as possible. We suggest that the association of
n elevated ratio of PVD to body weight with high mortality
eflects selection of a high-risk cohort, including very small
nfants in whom early surgery is mandatory because of the
omplexity of the underlying disease or poor clinical con-
ition and patients with a large annulus in a highly dilated
entricle with poor ventricular function, which was shown
o be related to higher mortality.11
For this reason we believe the use of the z score differ-
nce, as previously described,11 is a more suitable parameter
o analyze prosthesis–patient mismatch than the ratio of
VD to body weight. In contrast with the study of Eble and
olleagues,11 differences in survival or need for re-AVVR
etween patients with a “matched,” “oversized,” or “under-
ized” prosthetic valve in relation to the measured annulus
id not reach statistical difference.
imitations
e acknowledge that the lack of clinical data reflecting the
linical status of the patient at AVVR is an important
rawback of this report when discussing operative mortal-
ty. We think that this aspect is especially important in
nfants requiring valve surgery during the first year of life.
his is a retrospective study, rendering complete data col-
ecting difficult. Advancement in operative and periopera-
ive care may have affected outcome, although we were not
ble to detect this. The inclusion of patients with univen-
ricular hearts, who have a large ventricle and therefore a
arge native annulus, makes the calculation of the PAD
roblematic. Because we focused on the relationship be-
and Cardiovascular Surgery ● Volume 134, Number 3 755
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Dween the MAD and the PVD, this fact did not lead to
isinterpretation of data.
onclusions
his study shows that selection of prosthesis in systemic
VVR in small children is made on MAD rather than PAD.
espite the simplicity of the prosthesis/weight ratio and its
ssociation with increased mortality, this parameter does
ot compellingly reflect geometric disparity between the
rosthesis and the cardiac dimensions. There is a need to
lace smaller prosthetic valves at the surgeon’s disposal
ven if their use will be restrained to a limited portion of
atients. Although approximately half of the survivors re-
uire subsequent AVVR within 10 years, the operative risk
f re-AVVR is low. At the time of re-AVVR, the new valve
an be upsized. AVVR should be considered as a promising
herapeutic option after failed attempts of valvuloplasty and
hould be undertaken as long as the patient is in stable
linical condition.
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